TLR9 and diffuse large B-cell lymphoma: In this respect, these data provide evidence of clinical relevance, which will be useful in devising therapeutic trials with TLR9 agonists, such as oligodeoxynucleotides containing CpG motifs (CpG-ODN), in dogs with DLBCL.